Dennis Merkle
CDx Commercialization Lead Boehringer Ingelheim
Biotech Executive with 20 years of international and cross-functional experience in oncology, molecular diagnostics and drug development, from early/preclinical stages through to launch and life-cycle management of mature products.
Seminars
Tuesday 31st March 2026
Targeting DLL3 in Neuroendocrine Carcinomas; Establishing Novel Biomarkers in Novel Indications
5:50 pm
- DLL3 is an actionable target, expressed in a number of tumour types, but rarely in healthy tissues
- Extra-pulmonary neuroendocrine carcinomas (epNEC) are highly aggressive and, to date, do not include any approved targeted therapies as part of their treatment guidelines
- T-cell Engagers (TcEs) show promising activity in epNEC with high DLL3 expression, suggesting that DLL3 testing may become an important tool in the diagnostic work-up of these rare and hard-to-treat tumours
- AI can be considered to improve the diagnosis of epNEC and provide consistency in DLL3 interpretation
